Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
1.340
-0.040 (-2.90%)
At close: Aug 1, 2025, 4:00 PM
1.359
+0.019 (1.44%)
After-hours: Aug 1, 2025, 4:58 PM EDT

Company Description

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.

The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.

It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer.

It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals logo
CountryUnited States
Founded2014
IPO DateApr 3, 2020
IndustryBiotechnology
SectorHealthcare
Employees166
CEOJulie Eastland

Contact Details

Address:
10275 Science Center Dr., Suite 200
San Diego, California 92121
United States
Phone212 433 3791
Websitezentalis.com

Stock Details

Ticker SymbolZNTL
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$18.00
CIK Code0001725160
CUSIP Number98943L107
ISIN NumberUS98943L1070
Employer ID82-3607803
SIC Code2834

Key Executives

NamePosition
Julie M. Eastland M.B.A.Chief Executive Officer, President and Director
Andrea Paul J.D.Chief Legal Officer and Corporate Secretary
Vincent A. VultaggioSVice President of Finance and Principal Accounting Officer
Wendy ChangChief People Officer
Robert J. DiVasto P.E.Senior Vice President of Technical Operations
Dr. Ingmar Bruns M.D., Ph.D.Chief Medical Officer
Haibo WangChief Business Officer
Rajesh IsraniSenior Vice President of Regulatory Affairs and Medical Writing
Henry GuSenior Vice President and Head of Intellectual Property

Latest SEC Filings

DateTypeTitle
Jul 16, 2025SCHEDULE 13G/AFiling
Jun 18, 20258-KCurrent Report
Jun 2, 20258-KCurrent Report
May 23, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
May 20, 20258-KCurrent Report
May 14, 2025S-8Securities to be offered to employees in employee benefit plans
May 14, 202510-QQuarterly Report
May 14, 20258-KCurrent Report
May 14, 2025SCHEDULE 13G/AFiling
May 13, 2025SCHEDULE 13G/AFiling